g despite two commercial Novo Nordisk ® In H1 2021, Rybelsus ® sales were DKK 1,674 million Rybelsus ® has now been launched in 18 countries In the US: • Increasing breadth and awareness amongst HCPs • More than 80% of new prescriptions are new to the GLP-1 class • Full field force re-entry middle of May 2021 • Direct-to-consumer advertising continues Outside of the US: • In Japan, Rybelsus ® has reached a 0.7% modern oral antidiabetics (MOAD) value market scription data
Download PDF file